Advent France Biotechnology participe au tour d’amorçage de 4,2 millions d’euros d’Augustine Therapeutics
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia
Urania Therapeutics closes a €3.5M initial seed round
Nosopharm welcomes Jacques Biton and Frédéric Hammel to its supervisory board
Alaxia joins EU consortium to combat drug-resistant lung infections
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia
Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim
